WALTHAM, Mass.--(BUSINESS WIRE)--NeurAxon Inc., a developer of next-generation pain therapeutics, announced today that Lawrence E. Bloch, M.D., J.D., has been appointed Chief Executive Officer and a member of the Company’s Board of Directors. Dr. Bloch was most recently Chief Financial Officer and Chief Business Officer of NitroMed, Inc. “Larry’s demonstrated leadership abilities, experience in business development, and successful track record in both private and public financings will be crucial to NeurAxon as it continues to build its organization and advance its pipeline of internally generated product candidates,” commented Andrew Sandham, Chairman of the Board of Directors of NeurAxon. “Larry joins NeurAxon at a pivotal time as we anticipate Phase 1 data from NXN-188, our lead product candidate for the treatment of acute migraine. We are pleased to welcome Larry and look forward to accelerating NeurAxon’s growth and success under his leadership.”
